Relationship between autoantibodies against type 2 deiodinase and antithyroid autoantibodies in Graves’ disease using antithyroid drug therapy
Main Article Content
Abstract
Background: Previously, the presence of autoantibodies against type 2 deiodinase cys- and hom-peptides was investigated in Graves’ disease with relation to thyroid function, ophthalmopathy and therapy. The new design was to reveal the relationship among antithyroid antibodies involved in hormone synthesis.
Aim and scope: To demonstrate some regularity between the appearance of peptide autoantibodies and antithyroid antibodies against TSH receptor, thyroid peroxidase and thyroglobulin, the study followed the main path of hormone synthesis and the effect of antithyroid drug treatment. Has any effect of peptide autoantibodies on the titers of other autoantibodies?
Methods: The methods were described in our previous papers detailed. Autoantibodies against type 2 deiodinase peptides were detected with enzyme-linked immunosorbent assay in 78 patients with Graves’ disease and 30 controls. Thyroid hormones (TSH, FT4 and FT3) and antibodies against TSH receptor, thyroid peroxidase and thyroglobulin were measured with chemiluminescence immunoassay.
Results: The frequency of cys-peptide antibodies was greater in the new onset of Graves’ disease. Propylthiouracil treatment was associated with increased occurrence of cys-peptide antibodies (p<0.0069). No dose-dependency in methimazole treatment could be demonstrated for cys-peptide antibody levels. Antibodies against hom-peptide or both peptides demonstrated a strong relationship with the appearance of antithyroid antibodies. No peptide antibodies were associated with anti-thyroglobulin antibody positivity (0 cases out of 11 for hom-peptide, p<0.0071 and 0 cases out of 8 for both peptides, p<0.0251). In contrast, all cases with TSH receptor antibody positivity were positive for peptide antibodies (all cases out of 13 for hom-peptide, p<0.0139 and all cases out of 9 for both peptides, p<0.0470). TSH receptor antibody levels were relevantly decreased, when hom-peptide antibodies were present [24.35(15.68-37.8) vs 11.8(8.16-17.07) IU/l, p<0.0437].
Conclusion: The presence of hom-peptide antibodies was connected to the absence of antibodies against thyroglobulin and smaller anti-thyroid peroxidase antibody positivity. The presence and the high titers of TSH receptor antibodies demonstrated a close relationship with the appearance of hom-peptide antibodies. The relationship among the studied autoantibodies may depend on the alteration of thyroid hormone synthesis and the steric hindrance of targets and antithyroid drug treatment. Autoantibodies against type 2 deiodinase peptides can influence the therapeutical effectiveness.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Laurberg P, Vestergaard H, Nielsen S, et al. Sources of circulating 3,5,3’-triiodothyro¬nine in hyperthy¬roi¬dism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab. 2007;92:2149-2156.
3. Molnár I, Szentmiklósi AJ, Somogyiné-Vári É. Hyperthyroidism in patients with Graves’ ophthalmopathy, and thyroidal, skeletal and eye muscle specific type 2 deiodinase enzyme activities. Exp Clin Endocrinol Diab. 2017;125:514-521.
4. Yoshihara A, Luo Y, Ishido Y, et al. Inhibitory effects of methimazole and popylthiouracil on iodotyrosine deiodinase 1 in thyrocytes. Endocrine J. 2019; 6:349-357.
5. Molnár I. Deiodinase enzymes and their acti¬¬¬vi¬ties in Graves’ hyperthyroi¬dism. In: Gensure R, ed. Graves’ disease. London, UK: IntechOpen; 2021:113-130.
6. Fröhlich E, Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Frontiers in Immunology. 2017:fimmu.2017.00251. doi:10.3389/fimmu.2017.00251.
7. Molnár I, Szentmiklósi AJ, Gesztelyi R, Somogyiné-Vári É. Effect of antithy¬roid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves’ disease influencing the therapeutic efficacy. Clin Exp Med. 2019; 19:245-254.
8. Molnár I, Szombathy Z, Kovács I, Szentmiklósi JA. Immunohistochemical studies using immunized guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves’ sera. J Clin Immunol. 2007; 27:172-180.
9. Pearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: A phase I. study. Thyroid 2019; 29:1003-1011.
10. Nakahara R, Tsunekawa K, Yabe S, et al. Association of antipituitary antibody and type 2 iodothyronine deiodinase antibody in patients with autoimmune thyroid disease. Endocrine J. 2005;52:691-699.
11. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Frontiers Immunology. 2021;12: fimmu. 2021.548469. doi:10.3389/fimmu.2021.548469.
12. Bogusławska J, Godlewska M, Gajda E, Piekielko-Witkowska A. Cellular and molecular basis of thyroid autoimmunity. Eur Thyroid J. 2022:ETJ-21-0024. doi:10.1530/ETJ-21-0024.
13. Sawai Y, DeGroot LJ. Binding of human thyrotropin receptor peptides to a Graves’ disease-predisposing human leukocyte antigen class II molecule. J Clin Endocrinol Metab. 2000; 85:1176-1179.
14. Neumann S, Huang W, Titus S, et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. PNAS. 2009; 106:12471-12476.
15. Ungerer M, Faβbender J, Holthoff HP. Antigen-specific therapy of Graves’ disease and orbitopathy by induction of tolerance. Frontiers Landmark. 2018;23: 2044-2052.
16. Gao Y, Zhao M, Guo X, Xin G, Wang H. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res. 2004;30:205-213.
17. Roy G, Mugesh G. Anti-thyroid drugs and thyroid hormone synthesis: Effects of methimazole derivates on peroxidase-catalyzed reactions. J Am Chem Soc. 2005; 127:15207-15217.
18. Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and nechanism of action. Acc Chem Res. 2013;46:2706-2715.
19. Pérez de la Lastra JM, Baca-González V, González-Acosta S, et al. Antibodies targeting enzyme inhibition as potential tools for research and drug development. BioMol Concepts. 2021;12:215-232.
20. Mountz JD. Significance of increased circulating proteasome in autoimmune disease. J Rheumatol. 2002;29:2027-2030.
21. Kimura H, Caturegli P, Takahashi M, Suzuki K. New insights into the function of the immunoproteasome in immune and nonimmune cells. J Immunol Res. 2025:541984. doi:10.1155/2015/541984.
22. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR. Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degrada¬tion and requires interaction with the enzyme’s active center. Endo¬cri¬no¬logy. 2000;141:1127-1135.
23. Sagar GDV, Gereben B, Callebaut I, et al. Ubiquination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. Mol and Cell Biol. 2007;27:4774-4783.